Patents by Inventor Sudhirdas K. Prayaga
Sudhirdas K. Prayaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170190750Abstract: A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO), Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.Type: ApplicationFiled: January 13, 2017Publication date: July 6, 2017Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Changaram S. Venugopal, Sudhirdas K. Prayaga
-
Patent number: 9546200Abstract: A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO). Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.Type: GrantFiled: June 8, 2012Date of Patent: January 17, 2017Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Changaram S. Venugopal, Sudhirdas K. Prayaga
-
Publication number: 20140105906Abstract: A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO). Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.Type: ApplicationFiled: June 8, 2012Publication date: April 17, 2014Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Changaram S. Venugopal, Sudhirdas K. Prayaga
-
Patent number: 7291483Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-GX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: December 30, 2004Date of Patent: November 6, 2007Assignee: CuraGen CorporationInventors: Richard A. Shimkets, Sudhirdas K. Prayaga
-
Patent number: 7253266Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.Type: GrantFiled: June 17, 2002Date of Patent: August 7, 2007Assignee: CuraGen CorporationInventors: Richard A. Shimkets, Michael Jeffers, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E. A. Pena, John P. Alsobrook, II, Denise M. Lepley, Daniel K. Rieger, William Grosse
-
Patent number: 7056885Abstract: The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.Type: GrantFiled: July 3, 2000Date of Patent: June 6, 2006Assignee: CuraGen CorporationInventors: Michael Jeffers, Richard A. Shimkets, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein
-
Patent number: 6992170Abstract: Disclosed herein are novel human nucleic acid sequences that have homology to thymosin, ephrin A receptors, proteoglycans and fibromodulin. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these novel nucleic acids and proteins.Type: GrantFiled: October 9, 2001Date of Patent: January 31, 2006Assignee: CuraGen CorporationInventors: Sudhirdas K. Prayaga, Raymond J. Taupier, Jr., Raj Bandaru
-
Patent number: 6855806Abstract: Disclosed herein are novel human nucleic acid sequences. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these novel nucleic acids and proteins.Type: GrantFiled: October 12, 2000Date of Patent: February 15, 2005Assignee: Curagen CorporationInventors: Sudhirdas K. Prayaga, Raymond J. Taupier, Jr., Raj Bandaru
-
Publication number: 20040214759Abstract: In methods of using a fibroblast growth factor, such as for treating, preventing or delaying a proliferation-associated disorder, steps are provided to administer to a subject a therapeutically effective amount of a particular fibroblast growth factor polypeptide, or variant or fragment thereof.Type: ApplicationFiled: May 9, 2003Publication date: October 28, 2004Inventors: John P. Alsobrook, Enrique Alvarez, David W. Anderson, Joel S. Bader, Ferenc L. Boldog, Catherine E. Burgess, Rajeev A. Chillakuru, Lisa Deegler, Shlomit R. Edinger, Elma R. Fernandes, Linda Gorman, William M. Grosse, John L. Herrmann, Michael E. Jeffers, William J. LaRochelle, Denise M. Lepley, Henri S. Lichenstein, Kumar Namdev, Muralidhara Padigaru, Carol E. A. Pena, Sudhirdas K. Prayaga, Daniel K. Rieger, Richard A. Shimkets, Pascal Valax, Meijia Yang, Zachary Yim, Mei Zhong
-
Publication number: 20040116671Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: February 5, 2004Publication date: June 17, 2004Inventors: Sudhirdas K. Prayaga, Kumud Majumder, Bruce Taillon, Steven Kurt Spaderna, Kimberly Spytek, John MacDougall
-
Publication number: 20040048248Abstract: Disclosed herein are novel human nucleic acid sequences which encode endozepine-like polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving this novel human endozepine-like nucleic acid and protein.Type: ApplicationFiled: February 27, 2002Publication date: March 11, 2004Inventors: Sudhirdas K. Prayaga, Richard A. Shimkets, Kumud Majumder, Andrew Eisen, Corine A.M. Vernet, Steven K. Spaderna, Jason Baumgartner, Linda Gorman, Vladimir Gusev, Muralidhara Padigaru, Meera Patturajan, Velizar Tchernev, Li Li
-
Publication number: 20040018199Abstract: In methods of using an ephrin receptor, such as for treating, preventing or delaying a proliferation-associated disorder such as cancer, steps are provided to administer to a subject a therapeutically effective amount of an antibody directed to an ephrin receptor polypeptide, variant or fragment thereof.Type: ApplicationFiled: May 29, 2003Publication date: January 29, 2004Inventors: Raj Bandaru, Amitabha Chaudhuri, Katherine Fries, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Uriel M. Malyankar, Chean Eng Ooi, Sudhirdas K. Prayaga, Raymond J. Taupier
-
Publication number: 20040014120Abstract: The invention provides novel human transmembrane (NOVTRAN), neuromedin (NOVNEUR), gonadtropih (NOVGON), and interleukin-1 receptor antagonist (NOVINTRA A and B) proteins (NOVX proteins) and isolated nucleic acid molecules encoding the same. Also provided are antibodies that immunospecifically bind to NOVX polypeptides or polynucleotides, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which a NOVX polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states. Also provided are method of diagnosing and treating a lung disease associated with differential expression of human interleukin-1 epsilon.Type: ApplicationFiled: June 23, 2003Publication date: January 22, 2004Inventors: Catherine Burgess, Sudhirdas K. Prayaga, Richard A. Shimkets, Luca Rastelli, Bryan Zerhusen, Peter Mezes
-
Publication number: 20040006015Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.Type: ApplicationFiled: December 16, 2002Publication date: January 8, 2004Inventors: Ferenc L. Boldog, Catherine E. Burgess, Elma R. Fernandes, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Jeffrey Peterson, Sudhirdas K. Prayaga, Beth Rittman, Juliette B. Shimkets, Richard A. Shimkets, Meijia Yang
-
Publication number: 20030203426Abstract: Disclosed herein are novel human nucleic acid sequences that have homology to thymosin, ephrin A receptors, proteoglycans and fibromodulin. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these novel nucleic acids and proteins.Type: ApplicationFiled: October 9, 2001Publication date: October 30, 2003Inventors: Sudhirdas K. Prayaga, Raymond J. Taupier, Raj Bandaru
-
Publication number: 20030186433Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.Type: ApplicationFiled: June 17, 2002Publication date: October 2, 2003Inventors: Richard A. Shimkets, Michael Jeffers, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E. A. Pena, John P. Alsobrook, Denise M. Lepley, Daniel K. Rieger, William Grosse
-
Publication number: 20030153495Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the morality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.Type: ApplicationFiled: November 16, 2001Publication date: August 14, 2003Inventors: Henry S. Lichenstein, Michael E. Jeffers, Richard A. Shimkets, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine E. Burgess, Elma R. Fernandes, Beth Rittman, Juliette B. Shimkets, William J. LaRochelle
-
Patent number: 6600019Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: January 4, 2001Date of Patent: July 29, 2003Assignee: CuraGen CorporationInventors: Sudhirdas K. Prayaga, Kumud Majumder, Bruce Taillon, Steven Kurt Spaderna, Kimberly Spytek, John MacDougall
-
Publication number: 20030138926Abstract: The present invention provides novel polypeptides, termed PTMAX polypeptides, as well as polynucleotides encoding PTMAX polypeptides and antibodies that immunospecifically bind to PTMAX or a derivative, variant, mutant, or fragment of the PTMAX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the PTMAX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: June 15, 2001Publication date: July 24, 2003Inventors: Sudhirdas K. Prayaga, Corine Vernet, Richard A. Shimkets, Catherine E. Burgess, Kimberly A. Spytek, Velizar Tchernev
-
Publication number: 20030064919Abstract: The invention provides polypeptides, designated herein as NOV polypeptides, as well as polynucleotides encoding NOV polypeptides, and antibodies that immunospecifically-bind to NOV polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the NOV polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states.Type: ApplicationFiled: December 7, 2000Publication date: April 3, 2003Applicant: CURAGEN CORPORATIONInventors: Sudhirdas K. Prayaga, Richard A. Shimkets